Prognostic Value of ERM Gene Expression in Human Primary Breast Cancers
Open Access
- 1 November 2004
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 10 (21) , 7297-7303
- https://doi.org/10.1158/1078-0432.ccr-04-0593
Abstract
We measured the expression of ERM gene, a nuclear transcription factor belonging to the ets family, in a series of 364 unselected primary breast cancers from patients who underwent locoregional surgery in the Centre Oscar Lambret between May 1989 and December 1991. The expression of ERM was quantified with a real-time one-step reverse transcription-PCR assay based on the 5′-nuclease activity of the TaqDNA polymerase and with an Abi Prism 7700 Sequence Detector System (Applied Biosystems, Courtaboeuf, France). ERM was positively correlated (Spearman test) to epidermal growth factor receptor (EGFR; P < 0.001, r = 0.296) and to histoprognostic grading (P = 0.044, r = 0.112), whereas it was negatively correlated to estradiol receptors (P = 0.019, r = -0.124), HER3 (c-erbB-3; P = 0.01, r = −0.135), and HER4 (c-erbB-4; P = 0.003, r = −0.154). Using the χ2 test, a positive relationship was found between the expression of ERM and EGFR (χ2 = 7.795, P = 0.007). In overall survival studies, Cox univariate analyses demonstrated a prognostic value of ERM (P = 0.006; risk ratio, 2.95) besides the classical prognostic factors histoprognostic grading, node involvement, tumor size, estradiol receptors, progesterone receptors, EGFR, HER3, and HER4. In multivariate analyses, ERM preserved its prognostic value (P = 0.004; risk ratio, 3.779) together with histoprognostic grading, tumor size, estradiol receptors, and progesterone receptors. In relapse-free survival studies, univariate analyses demonstrated that histoprognostic grading, node involvement, tumor size, and HER4 were prognostic factors. These parameters, except histoprognostic grading, retained their prognostic value in multivariate analyses. This study demonstrates for the first time that ERM gene expression is an independent adverse prognostic factor for overall survival in breast cancer patients.Keywords
This publication has 32 references indexed in Scilit:
- Expression of ets-related transcriptional factor E1AF is associated with tumor progression and over-expression of matrilysin in human gastric cancerCarcinogenesis: Integrative Cancer Research, 2003
- Expression of PEA3/E1AF/ETV4, an Ets-related transcription factor, in breast tumors: positive links to MMP2, NRG1 and CGB expressionCarcinogenesis: Integrative Cancer Research, 2003
- Association of ets‐related transcriptional factor E1AF expression with tumour progression and overexpression of MMP‐1 and matrilysin in human colorectal cancerThe Journal of Pathology, 2003
- The PEA3 Subfamily of Ets Transcription Factors Synergizes with β-Catenin–LEF-1 To Activate Matrilysin Transcription in Intestinal TumorsMolecular and Cellular Biology, 2001
- HER2/Neu and the Ets transcription activator PEA3 are coordinately upregulated in human breast cancerOncogene, 1997
- Differential expression patterns of the PEA3 group transcription factors through murine embryonic developmentOncogene, 1997
- Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization.Genome Research, 1995
- Molecular cloning and characterization of PEA3, a new member of the Ets oncogene family that is differentially expressed in mouse embryonic cells.Genes & Development, 1992
- IGF-1 receptors (IGF1-R) in human breast cancer. Relation with estradiol, progesterone and prolactin receptors (ER, PgR, PRL-R)Journal of Steroid Biochemistry, 1987
- Standardization of steroid receptor assays in human breast cancer—IV. Long-term within- and between-laboratory variation of estrogen and progesterone receptor assaysEuropean Journal of Cancer and Clinical Oncology, 1986